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efits and risks of chelation therapy in this patient population
are necessary. But like Porter and Garbowski,1 the panel was
concerned that the evidence from randomized trials of chela-
tion therapy inpatientswithSCDreceiving transfusion therapy
may require up to 2 decades to test end points such as death
or hepatic cirrhosis.
It is not clear that such randomizationwould evenbe con-
sidered feasibleorethical.Basedonthis information, thepanel
chose to make a moderate strength recommendation to con-
sider chelation therapy in patients with SCD and signs of iron
overload.
Dr Klings and colleagues address the serious problem of
pulmonary hypertension in patients with SCD. Even though
our guidelines differ from those of the American Thoracic
Society for screening asymptomatic patients with SCD for
pulmonary hypertension, we strongly support their recom-
mendation for the conduct of prospective outcome studies
of tricuspid regurgitant jet velocity screening accompanied
by evaluation of pharmacological intervention in patients
in whom cardiac catheterization confirms a diagnosis of
pulmonary arterial hypertension or pulmonary venous
hypertension.4
We do agree that no evidence exists to demonstrate that
thescreeningofasymptomaticpatients changesoutcomes.We
hope that continued considerationwill also be given to quan-
tifying the currently unknown number of asymptomatic in-
dividuals with treatable contributory factors as well as fur-
therclarificationof thebenefitsandharmsofscreening toallow
risk stratification.
We agree with Klings and colleagues that there is contin-
ued underuse of SCD-specific therapies. One of the primary
goals of our guideline sponsored by theNationalHeart, Lung,
andBlood Institutewas toenhance theavailabilityofhydroxy-
urea and transfusion therapy for all SCD treatment candi-
dates, in agreement with Klings et al.
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Reanalyses of Trial Results
To theEditorWeagreewithDrEbrahimandcolleagues1 that re-
analyses of clinical trial data provide an important opportu-
nity to better understand trial results and thatmore indepen-
dent reanalyses are needed. However, the estimate of the
number of reanalyses published prior to March 9, 2014, re-
ported by Ebrahimet al1 is incorrect, possibly by a substantial
margin.
Ebrahim et al1 reported that their MEDLINE search iden-
tified 37 reanalyses of data from previously published ran-
domized clinical trials. However, the authors limited their
search to manuscripts categorized as a clinical trial in
MEDLINE. This is problematic because many reanalyses are
given themore general classification of journal article and so
are not identified in searches restricted to clinical trial ar-
ticles.
Examples of this can be found among the reanalyses of
the data from the trial of tissue plasminogen activator for
ischemic stroke sponsored by the National Institute of Neu-
rological Disorders and Stroke (NINDS). The original analy-
sis was published in 1995.2 A recent Cochrane review3 iden-
tified at least 7 reanalyses of the data from the NINDS trial.
Each of these reanalyses meets the criteria defined by Ebra-
him et al1; however, none was identified using their search
method. Five of these reanalyses are not classified within
MEDLINE as clinical trials. The same problem may be true
of other reanalyses.
As noted by IBM Quality Manager H. James Harrington,
“measurement is the first step that leads to control and even-
tually improvement.”4 Obtaining an accurate measure of the
number of reanalyses being published and defining a search
method that can consistently generate this number is essen-
tial to assesswhether newpolicies (such as those called for by
Krumholz and Peterson5) result in the increase in reanalyses
needed to optimize understanding of trial results.
A search unrestricted by publication type should provide
amoreaccuratemeasureof thenumberof reanalysesbut adds
considerably to the workload of the search. Steps to improve
the consistencyof classificationof articles bypublication type
withinMEDLINEmayprovidea long-termsolution to this chal-
lenge.
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In ReplyDrs Platts-Mills and Joneshave raised apotential con-
cernwith the search strategy used in our study on reanalyses
of randomized clinical trial data, specifically with respect to
our restriction to studies indexed as a clinical trial publica-
tion type inMEDLINE.Weagreewith themthat a strategywith
no restriction to clinical trials publication typewouldbemore
sensitive in detecting reanalyses.
However, performing such a search would yield a total
of 112 330 citations (limited to March 9, 2014, as per our
original search). Screening this number of citations would
be a daunting task and may not be a valuable use of
resources if the output of additional studies retrieved would
be few in number compared with the studies retrieved in
our original search.
We have attempted to get an estimate of how many
studies we potentially missed by using a simplified search
with (reanalysis [ti] OR reanalysis [ti]) NOT Clinical Trial
[PT] AND random* (limited to March 9, 2014) that would
capture the reanalysis of the NINDS rt-PA Stroke Study.
Besides the NINDS study, we also identified eligible reanaly-
ses for 3 more trials. Two of the 4 new eligible trials1-4 had
their reanalyses completed by independent authors or
committees,2,3 and the other 2 had reanalyses completed by
the same research group or included authors from the origi-
nal study.1,4
Reasons for completing reanalyses included theuse of in-
tention-to-treatprinciples (comparedwithper-protocol analy-
ses used in the original article),1 correction for subgroup
imbalances,3 use of a method for identifying latent trajecto-
ries (latent class growth analysis),4 and comparisonof thepri-
mary end point using a change in the definition of the
outcome.2
Of the 4 reanalyses, 1 found that the experimental treat-
ment (bilavirudin)wassignificantlymoreeffectiveandhad less
bleeding complications than control (heparin),1 whereas the
original analysis had shown no significant difference in effi-
cacy, soperhaps thiswould lead tomorepatientsbeing treated
with bilavirudin. Another reanalysis4 found effects for latent
classes of participants that were not obvious in the original
analysis, so it is possible that different patientsmaybe treated
differently based on these results.
We have no doubt that a few more trials must have been
missedgiven the imperfect sensitivity of any searches and the
lack of a standard tag for reanalyses in PubMed. However, we
believe that it is unlikely that the number of missed pub-
lished reanalyses is large. Measures to improve awareness of
the importance and systematic indexing of reanalyses in
PubMed are certainly required.
Nonetheless,ourmainconclusions thatpublishedreanaly-
ses are currently rare, almost always involve authors of the
original analyses, and about one-third reachdifferent conclu-
sions still hold true. If there weremore interest in publishing
reanalyses regardless of their results,we suspect that thepro-
portion of those claiming that they had found something dif-
ferent from the original analysis would decrease.
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Risk Profile of Clinical Trial Participants
To the Editor In their research letter, Dr Udell and colleagues1
stated that clinical trial participantshada lower riskprofile and
amore favorable prognosis comparedwith the broader popu-
lation included in the National Cardiovascular Data Registry
(NCDR) Acute Coronary Treatment and Intervention Out-
comes Network Registry–Get With The Guidelines.
It is likely that these differences would be more pro-
nounced if clinical trial participants were compared with pa-
tients with myocardial infarction in the broader US popula-
tion because participation in the NCDR is voluntary and
includes participation by only 5% of US hospitals.1,2 In addi-
tion, the data would be put in better perspective if the age of
the patients with myocardial infarction in the NCDR and the
rates of diagnostic cardiac catheterization and percutaneous
coronary intervention were compared with a more inclusive
database such as the Nationwide Inpatient Sample.2
It would also be interesting to compare the characteris-
tics of patients presenting to the NCDR hospitals that did and
did not enroll patients in clinical trials because there may be
relevant differences in clinical presentation andoutcomes. In
addition, the better outcomes of participants in clinical trials
maybeexpected fromtheexclusion criteria of the clinical trial
protocols, self-selection of clinical trial participants (who of-
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